Currently, clinical trials evaluating STING agonists (either as monotherapy or in combination with ICIs, radiotherapy or chemotherapy) for the treatment of solid tumours such as BCa, RCC and PCa have been extensively initiated (Table 1). This evidence concerns the gene STING1 and renal cell carcinoma.